WH. Immunologic and structural analysis of eight novel domain-deletion b 3 integrin peptides designed for detection of HPA-1 antibodies. J Thromb Haemost 2008; 6: 366-75.See also Stafford P, Garner SF, Huiskes E, Kaplan C, Kekomaki R, Santoso S, Tsuno NH, Watkins NA, Ouwehand WH. Three novel b3 domaindeletion peptides for the sensitive and specific detection of HPA-4 and six low frequency b3-HPA antibodies. This issue, pp 376-83.Summary. Background: The single-nucleotide polymorphism (SNP) rs5918 in the ITGB3 gene defines the human platelet antigen-1 (HPA-1) system encoding a Leu (HPA-1a) or Pro (HPA-1b) at position 33. HPA-1 antibodies are clinically the most relevant in the Caucasoid population, but detection currently requires a IIb b 3 integrin from the platelets of HPAgenotyped donors. Objectives: We set out to define the b 3 integrin domains required for HPA-1a antibody binding and produce recombinant soluble b 3 peptides for HPA-1 antibody detection. Methods: We designed two sets (1a and 1b) of four soluble b 3 domain-deletion peptides (DSDL, DbA, PSIHybrid, PSI), informed by crystallography studies and computer modeling. The footprints of three human HPA-1a-specific phage antibodies were defined by analyzing binding patterns to the b 3 peptides and canine platelets, and models of antibodyantigen interfaces were derived. Specificity and sensitivity for HPA-1a detection were assessed using sera from 140 cases of fetomaternal alloimmune thrombocytopenia (FMAI-T). Results: Fusion of recombinant proteins to calmodulin resulted in high-level expression in Drosophila S2 cells of all eight b 3 peptides. Testing of FMAIT samples indicated that DbA-Leu33 is the superior peptide for HPA-1a antibody detection, with 96% sensitivity and 95% specificity. The existence of type I and II categories of HPA-1a antibodies was confirmed by the study of HPA-1a phage antibody footprints and the reactivity pattern of clinical samples with the four b 3 -Leu33 peptides, but there was no correlation between antibody category and clinical severity of FMAIT. Conclusions: Soluble recombinant b 3 peptides can be used for detection of clinical HPA-1a antibodies.